{"id":469,"date":"2003-03-01T12:04:00","date_gmt":"2003-03-01T11:04:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2003\/pravastatin-wirksamkeit-in-der-allhat-llt-studie-nicht-nachweisbar"},"modified":"2022-03-17T14:10:21","modified_gmt":"2022-03-17T13:10:21","slug":"pravastatin-wirksamkeit-in-der-allhat-llt-studie-nicht-nachweisbar","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2003\/pravastatin-wirksamkeit-in-der-allhat-llt-studie-nicht-nachweisbar","title":{"rendered":"Pravastatin-Wirksamkeit in der ALLHAT-LLT-Studie nicht nachweisbar"},"content":{"rendered":"<p>Die Patienten der ALLHAT-Studie (1) wurden zus\u00e4tzlich offen randomisiert zu 40 mg\/d Pravastatin (Mevalotin protect, Pravasin protect) bzw. &#8222;normaler Therapie&#8220; (ALLHAT-LLT-Studie; 2). Eingeschlossen wurden 10355 Patienten, \u00e4lter als 54 Jahre, mit arterieller Hypertonie und einem weiteren Risikofaktor f\u00fcr Atherosklerose, wenn der LDL-Cholesterinwert nicht \u00fcber 189 mg\/dl war (bei Patienten mit erwiesener Atherosklerose 129 mg\/dl). Die [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die Patienten der ALLHAT-Studie (1) wurden zus\u00e4tzlich offen randomisiert zu 40 mg\/d Pravastatin (Mevalotin protect, Pravasin protect) bzw. &#8222;normaler Therapie&#8220; (ALLHAT-LLT-Studie; 2). Eingeschlossen wurden 10355 Patienten, \u00e4lter als 54 Jahre, mit arterieller Hypertonie und einem weiteren Risikofaktor f\u00fcr Atherosklerose, wenn der LDL-Cholesterinwert nicht \u00fcber 189 mg\/dl war (bei Patienten mit erwiesener Atherosklerose 129 mg\/dl). Die [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[800,60,451,449,71,180,68,455,453,456,65,801,56,443],"class_list":["post-469","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-allhat-llt-studie","tag-apoplektischer-insult","tag-cholesterinsynthese-hemmer","tag-cse-hemmer","tag-herzinfarkt","tag-herzinsuffizienz","tag-hirninfarkt","tag-hmg-coa-reduktase-hemmer","tag-hypercholesterinaemie","tag-lipidsenker","tag-myokardinfarkt","tag-pravastatin","tag-schlaganfall","tag-statine"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/469","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=469"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/469\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=469"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=469"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}